Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Public ClinicalTrials.gov record NCT00068081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Study identification
- NCT ID
- NCT00068081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- NeurogesX
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Interventions
- Capsaicin Dermal Patch Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Mar 5, 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NeurogesX Investigational Site | Mesa | Arizona | 85210 | — |
| NeurogesX Investigational Site | Peoria | Arizona | 85381 | — |
| NeurogesX Investigational Site | Phoenix | Arizona | 85032 | — |
| NeurogesX Investigational Site | Duarte | California | 91010 | — |
| NeurogesX Investigational Site | Santa Rosa | California | 95403 | — |
| NeurogesX Investigational Site | Boynton Beach | Florida | 33437 | — |
| NeurogesX Investigational Site | Bradenton | Florida | 34205 | — |
| NeurogesX Investigational Site | Fort Myers | Florida | 33907 | — |
| NeurogesX Investigational Site | Naples | Florida | 34102 | — |
| NeurogesX Investigational Site | Tampa | Florida | 33614 | — |
| NeurogesX Investigational Site | Atlanta | Georgia | 30328 | — |
| NeurogesX Investigational Site | Marietta | Georgia | 30060 | — |
| NeurogesX Investigational Site | Brighton | Massachusetts | 02135 | — |
| NeurogesX Investigational Site | St Louis | Missouri | 63108 | — |
| NeurogesX Investigational Site | St Louis | Missouri | 63141 | — |
| NeurogesX Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| NeurogesX Investigational Site | Dallas | Texas | 75235 | — |
| NeurogesX Investigational Site | San Antonio | Texas | 78229 | — |
| NeurogesX Investigational Site | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00068081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2008 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00068081 live on ClinicalTrials.gov.